J&J Joins Chase for Hot Immunology Target With $850M Proteologix Acquisition

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Johnson & Johnson’s Proteologix acquisition adds a pipeline of bispecific antibodies, including an experimental treatment for asthma and atopic dermatitis. It’s the latest M&A deal involving molecules addressing TSLP, a key signaling protein involved in inflammation.

The post J&J Joins Chase for Hot Immunology Target With $850M Proteologix Acquisition appeared first on MedCity News.

Leave a Replay

Sign up for our Newsletter

Contact Us